This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by BARBUI, C.
Right arrow Articles by HOTOPF, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by BARBUI, C.
Right arrow Articles by HOTOPF, M.
The British Journal of Psychiatry (2001) 178: 129-144
© 2001 The Royal College of Psychiatrists

REVIEW ARTICLE

Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials{dagger}

CORRADO BARBUI, MD

Department of Psychological Medicine, Institute of Psychiatry, London, and Istituto di Ricerche Farmacologiche "Mario Negri" Milan, and Dipartimento di Medicina e Sanità Pubblica, Sezione di Psichiatria, Università di Verona, Italy

MATTHEW HOTOPF, MRCPsych

Department of Psychological Medicine, Guy's, King's and St Thomas' Schools of Medicine, and Institute of Psychiatry, London

Correspondence: Dr Corrado Barbui, Istituto di Ricerche Farmacologiche "Mario Negri", Via Eritrea 62, 20157 Milano, Italy. Tel: 0039 02 39014 431; fax: 0039 02 33 2000 49; e-mail: barbui{at}marionegri.it

Declaration of interest None.

{dagger} See editorial, pp. 99-100, this issue.

Background Tricyclic antidepressants have similar efficacy and slightly lower tolerability than selective serotonin reuptake inhibitors (SSRIs). However, there are no systematic reviews assessing amitriptyline, the reference tricyclic drug, v. other tricyclics and SSRIs directly.

Aims To review the tolerability and efficacy of amitriptyline in the management of depression.

Method A systematic review of randomised controlled trials (RCTs) comparing amitriptyline with other tricyclics/heterocyclics or with an SSRI.

Results We reviewed 186 RCTs. The overall estimate of the efficacy of amitriptyline revealed a standardised mean difference of 0.147 (95% CI 0.05-0.243), significantly favouring amitriptyline. The overall OR for dropping out was 0.99 (95% CI 0.91-1.08) and that for side-effects was 0.62 (95% CI 0.54-0.70), favouring the control drugs. With drop-outs included as treatment failures, the estimate of the effectiveness of amitriptyline v. tricyclics/heterocyclics and SSRIs showed a 2.5% difference in the proportion of responders in favour of amitriptyline (number needed to treat 40, CI 21-694; OR 1.12 (95% CI 1.01-1.24)).

Conclusions Amitriptyline is less well tolerated than tricyclics/heterocyclics and SSRIs, but slightly more patients treated on it recover than on alternative antidepressants.




This article has been cited by other articles:


Home page
 Evid. Based Ment. HealthHome page
C. Barbui, A. Cipriani, T. A Furukawa, G. Salanti, J. P T Higgins, R. Churchill, N. Watanabe, A. Nakagawa, I. M Omori, and J. R Geddes
Making the best use of available evidence: the case of new generation antidepressants: A response to: Are all antidepressants equal?
Evid. Based Ment. Health, November 1, 2009; 12(4): 101 - 104.
[Full Text] [PDF]

Home page
 Adv. Psychiatr. Treat.Home page
P. J. Cowen
New drugs, old problems: REVISITING... PHARMACOLOGICAL MANAGEMENT OF TREATMENT-RESISTANT DEPRESSION
Adv. Psychiatr. Treat., January 1, 2005; 11(1): 19 - 27.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
C. Barbui
Antidepressants and the Risk of Suicidal Behaviors
JAMA, December 15, 2004; 292(23): 2833 - 2833.
[Full Text] [PDF]

Home page
 J PsychopharmacolHome page
M. T. Grauer and M. Uhr
P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline
J Psychopharmacol, March 1, 2004; 18(1): 66 - 74.
[Abstract] [PDF]

Home page
 Am J EpidemiolHome page
R. Hubbard, P. Farrington, C. Smith, L. Smeeth, and A. Tattersfield
Exposure to Tricyclic and Selective Serotonin Reuptake Inhibitor Antidepressants and the Risk of Hip Fracture
Am. J. Epidemiol., July 1, 2003; 158(1): 77 - 84.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
D. SMITH, C. DEMPSTER, J. GLANVILLE, N. FREEMANTLE, and I. ANDERSON
Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis
The British Journal of Psychiatry, May 1, 2002; 180(5): 396 - 404.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
M. PERCUDANI, G. BELLONI, A. CONTINI, and C. BARBUI
Monitoring community psychiatric services in Italy: differences between patients who leave care and those who stay in treatment
The British Journal of Psychiatry, March 1, 2002; 180(3): 254 - 259.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
G. Ranjith, V. Duddu, and K. S. Jacob
Psychiatric services in developing countries Author's response
The British Journal of Psychiatry, October 1, 2001; 179 (4): 368 - 369.
[Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
D. Owens, A. House, and C. Thompson
Declarations of interestAuthor's reply
The British Journal of Psychiatry, August 1, 2001; 179(2): 175 - 175.
[Full Text] [PDF]

Home page
 Br Med BullHome page
I. M Anderson
Meta-analytical studies on new antidepressants
Br. Med. Bull., March 1, 2001; 57(1): 161 - 178.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
C. THOMPSON
Amitriptyline: still efficacious, but at what cost?
The British Journal of Psychiatry, February 1, 2001; 178(2): 99 - 100.
[Full Text] [PDF]